A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke

Gil Benedek, Wenbin Zhu, Nicole Libal, Amanda Casper, Xiaolin Yu, Roberto Meza-Romero, Arthur A. Vandenbark, Nabil J. Alkayed, Halina Offner

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Chemoattraction of leukocytes into the brain after induction of middle cerebral artery occlusion (MCAO) increases the lesion size and worsens disease outcome. Our previous studies demonstrated that partial MHC class II constructs can reverse this process. However, the potential application of pMHC to human stroke is limited by the need to rapidly match recipient MHC class II with the β1 domain of the pMHC construct. We designed a novel recombinant protein comprised of the HLA-DRα1 domain linked to MOG-35-55 peptide but lacking the β1 domain found in pMHC and treated MCAO after 4 h reperfusion in humanized DR2 mice. Infarct volumes were quantified after 96 h reperfusion and immune cells from the periphery and CNS were evaluated for expression of CD74 and other cell surface, cytokine and pathway markers. This study demonstrates that four daily treatments with DRα1-MOG-35-55 reduced infarct size by 40 % in the cortex, striatum and hemisphere, inhibited the migration of activated CD11b+CD45high cells from the periphery to the brain and reversed splenic atrophy. Furthermore, DRα1-MOG-35-55 bound to CD74 on monocytes and blocked both binding and downstream signaling of macrophage migration inhibition factor (MIF) that may play a key role in infarct development. The novel DRα1-MOG-35-55 construct is highly therapeutic in experimental stroke and could be given to all patients at least 4 h after stroke onset without the need for tissue typing due to universal expression of DRα1 in humans.

Original languageEnglish (US)
Pages (from-to)37-45
Number of pages9
JournalMetabolic brain disease
Volume29
Issue number1
DOIs
StatePublished - Mar 2014

Keywords

  • Immunotherapy
  • Inflammation
  • MHC class II invariant chain
  • Recombinant T-cell receptor Ligand
  • Stroke

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke'. Together they form a unique fingerprint.

  • Cite this